Jagsonpal Pharmaceuticals enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,547	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
19.1	10.0	11.2	12.8	11.1
1,528	—	—	—	—
−19.1	−10.0	−11.2	−12.8	−11.1
₹228.11	—	—	—	—

244	276	240	187	159

5.08×	—	—	—	—
24.86×	—	—	—	—
28.87×	—	—	—	—
32.63×	—	—	—	—
301	287	269	209	237
61.4	58.1	51.1	23.1	34.2
52.9	48.6	42.9	21.4	32.9
—	46.8	55.3	35.2	40.1
46.8	46.8	55.0	34.9	39.8
—	46.8	54.9	34.9	39.7
—	0.0	0.3	0.2	0.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersAMRUTANJAN NGLFINE SYNCOMF HESTERBIO SIGACHI LINCOLN WINDLASMcap ₹1,547 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,546.6
- Cash, Equiv & ST Investments	11.1	12.8	11.2	10.0	19.1
Enterprise Value	—	—	—	—	1,527.5
Net Debt (memo)	-11.1	-12.8	-11.2	-10.0	-19.1
EV per Share	—	—	—	—	228.11

Total Capital	158.9	187.4	240.0	276.2	243.8

EV/Sales	—	—	—	—	5.08
EV/EBITDA	—	—	—	—	24.86
EV/EBIT	—	—	—	—	28.87
EV/Free Cash Flow	—	—	—	—	32.63
Reference Items — Trailing FY Values
Sales	236.7	208.7	268.7	287.2	300.8
EBITDA	34.2	23.1	51.1	58.1	61.4
EBIT	32.9	21.4	42.9	48.6	52.9
Operating Cash Flow	40.1	35.2	55.3	46.8	—
Free Cash Flow	39.8	34.9	55.0	46.8	46.8
FCFF (free cash flow to the firm)	39.7	34.9	54.9	46.8	—
Capital Expenditure	0.3	0.2	0.3	0.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.